Skyscape Web Viewer : Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs : Main Index

View All
Mabs
prostate cancer 17α-hydroxylase/17-lyase (CYP17) inhibitors and rogen deprivation therapy apalutamide darolutamide GnRH agonists and antagonists schematic structure of GnRH agonist relative to native GnRH treatment goal abiraterone and its prodrug, abiraterone acetate and rogen receptor (AR) activation by dihydrotestosterone (DHT) AR antagonists (antiand rogens) enzalutamide overview steroidal and nonsteroidal antiand rogens
mammalian target of rapamycin (mTOR) Transplant-Related Agents Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer
mantle cell lymphoma (MCL) DNA Repair, Apoptotic Pathways, CDK Inhibitors Answer 11.5 Targeted Therapies (Small Molecules)
MAPK
marginal zone lymphoma (MZL) Targeted Therapies (Small Molecules) Answer 11.5
maximal tolerated dose (MTD) Drug Approval and Regulatory Issues Answer 16.1 Question 16.2
maximum plasma concentration (Cmax)
MDR
MDSs
melphalan (Mel)
MESNA
methotrexate (MTX) Answer 4.1 Answer 4.3 Antimetabolites: Antifolates Question 4.3 Question 4.5 Answer 4.2 Answer 4.5 Question 4.2 Question 4.4
MGMT
minimal residual disease (MRD) Answer 13.1 Immunotherapeutics Including Vaccines, Bispecifics, CAR-T, and Checkpoint Inhibitors
mismatch repair deficiency (MMRd)
MM
MMF
molecular pharmacological audit trial (MoPhAT)
monoclonal antibodies (Mabs) class and target Monoclonal Antibodies Including Immunoconjugates and Cytokine-Directed Agents naked prevention and management of infusion-related reactions radioimmunoconjugates uses Answer 12.1 drug conjugates Multiple Myeloma as a Paradigm for Multi-Targeted Intervention overview Question 12.1 structure and classification
MoPhAT
MPN
MRP
MTD
mTORC1
MTX
multidrug-resistant protein (MRP)
mycophenolate mofetil (MMF)
myelodysplastic syndromes (MDSs)
MAC